INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 178 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $906 | -7.1% | 17,400 | +13.0% | 0.01% | 0.0% |
| Q2 2023 | $975 | +52.6% | 15,400 | +30.5% | 0.01% | +25.0% |
| Q1 2023 | $639 | +2.4% | 11,800 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $624 | -99.9% | 11,800 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $549,000 | -18.5% | 11,800 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $674,000 | -6.6% | 11,800 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $722,000 | -10.4% | 11,800 | -23.4% | 0.00% | 0.0% |
| Q4 2021 | $806,000 | +40.4% | 15,400 | 0.0% | 0.00% | +33.3% |
| Q3 2021 | $574,000 | -8.7% | 15,400 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $629,000 | +62.5% | 15,400 | +35.1% | 0.00% | +50.0% |
| Q1 2021 | $387,000 | +6.6% | 11,400 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $363,000 | +23.9% | 11,400 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $293,000 | -50.0% | 11,400 | -50.0% | 0.00% | 0.0% |
| Q2 2020 | $586,000 | – | 22,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |